Adularia
Adularia is a biotechnology company pioneering precision cancer immunotherapy by leveraging the symbiotic interplay between gut microbes and the immune system. They develop novel small molecule therapies that activate tumor-residing macrophages to trigger potent anti-tumor immune responses, enhancing the body's natural defenses against cancer. Their approach uses AI-powered drug discovery to optimize molecules for improved efficacy and bioavailability. The company is led by a team of experienced scientists and executives with backgrounds in oncology, immunology, and drug development, positioning Adularia at the forefront of next-generation immuno-oncology therapies.
Adularia
Adularia is a biotechnology company pioneering precision cancer immunotherapy by leveraging the symbiotic interplay between gut microbes and the immune system. They develop novel small molecule therapies that activate tumor-residing macrophages to trigger potent anti-tumor immune responses, enhancing the body's natural defenses against cancer. Their approach uses AI-powered drug discovery to optimize molecules for improved efficacy and bioavailability. The company is led by a team of experienced scientists and executives with backgrounds in oncology, immunology, and drug development, positioning Adularia at the forefront of next-generation immuno-oncology therapies.